Defective Differentiation of Myeloid and Plasmacytoid Dendritic Cells in Advanced Cancer Patients is not Normalized by Tyrosine Kinase Inhibition of the Vascular Endothelial Growth Factor Receptor

Defective Differentiation of Myeloid and Plasmacytoid Dendritic Cells in Advanced Cancer Patients is not Normalized by Tyrosine Kinase Inhibition of the Vascular Endothelial Growth Factor Receptor

Saved in:

Bibliographic Details
Main Authors:	T. D. de Gruijl, G. Giaccone, R. J. Scheper, H. van Cruijsen, K. Hoekman, B. C. Kuenen, A. J. M. van den Eertwegh, A. G. M. Stam
Format:	Article
Language:	English
Published:	Wiley 2007-01-01
Series:	Clinical and Developmental Immunology
Online Access:	http://dx.doi.org/10.1155/2007/17315
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Plasmacytoid Dendritic Cells: From Heart to Vessels
by: Rosalinda Sorrentino, et al.
Published: (2010-01-01)

Modulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
by: Li Zhang, et al.
Published: (2023-01-01)

Characteristics of Plasmacytoid Dendritic Cell and CD4+ T Cell in HIV Elite Controllers
by: Jean-Philippe Herbeuval, et al.
Published: (2012-01-01)

Antigen Gene Transfer to Human Plasmacytoid Dendritic Cells Using Recombinant Adenovirus and Vaccinia Virus Vectors
by: Hetty J. Bontkes, et al.
Published: (2005-01-01)

Promoting ER stress in a plasmacytoid dendritic cell line drives fibroblast activation
by: Beatriz H. Ferreira, et al.
Published: (2025-02-01)

A Rare Case of Blastic Plasmacytoid Dendritic Cell Neoplasm Occurred in Postchemotherapy of Breast Cancer
by: Jiankun Tong, et al.
Published: (2023-01-01)

Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
by: Evan Pisick, et al.
Published: (2004-01-01)

Treatment Interruption and Regimen Change in Firstgeneration versus Second-generation Tyrosine Kinase Inhibitors used as First-line Therapy for Chronic Myeloid Leukemia
by: Melea A. Ward, et al.
Published: (2015-04-01)

Metabolic deficiencies underlie reduced plasmacytoid dendritic cell IFN-I production following viral infection
by: Trever T. Greene, et al.
Published: (2025-02-01)

TSG-6 Downregulates IFN-Alpha and TNF-Alpha Expression by Suppressing IRF7 Phosphorylation in Human Plasmacytoid Dendritic Cells
by: L. Kui, et al.
Published: (2017-01-01)

Regulation of Endothelial Adherens Junctions by Tyrosine Phosphorylation
by: Alejandro Pablo Adam
Published: (2015-01-01)

USP8‐Dependent Family Tyrosine Kinase Promotes the Malignant Progression of Esophageal Squamous Cell Carcinoma by Upregulating Protein Tyrosine Kinase 2 Expression
by: Yuechang Wu, et al.
Published: (2025-01-01)

Role of Bruton's Tyrosine Kinase in B Cell Development
by: Alex Maas, et al.
Published: (2001-01-01)

Protein tyrosine kinase but not protein kinase C inhibition blocks receptor induced alveolar macrophage activation
by: K. Pollock, et al.
Published: (1993-01-01)

Baicalin and Baicalein Inhibit Src Tyrosine Kinase and Production of IL-6
by: Dubravko Jelić, et al.
Published: (2016-01-01)

Synergistic Stimulation with Different TLR7 Ligands Modulates Gene Expression Patterns in the Human Plasmacytoid Dendritic Cell Line CAL-1
by: Tobias Hilbert, et al.
Published: (2015-01-01)

Blastic plasmacytoid dendritic cell neoplasm: a Swiss case series of a very rare disease and a structured review of the literature
by: Ramona Meier-Lienhard, et al.
Published: (2025-01-01)

Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia
by: Benjamin M. Heyman, et al.
Published: (2025-02-01)

Muscle-Specific Tyrosine Kinase-Associated Myasthenia Gravis: A Neuromuscular Surprise
by: Hassam Ali, et al.
Published: (2021-01-01)

In Vitro Activation and Inhibition of Recombinant EGFR Tyrosine Kinase Expressed in Escherichia coli
by: Jihene Elloumi-Mseddi, et al.
Published: (2013-01-01)

Anti-microbial cetylpyridinium chloride suppresses mast cell function by targeting tyrosine phosphorylation of Syk kinase
by: Bright Obeng, et al.
Published: (2024-12-01)

Impact of First- and Second-Generation Tyrosine Kinase Inhibitors on the Development of Graft-Versus-Host Disease in Individuals with Chronic Myeloid Leukemia: A Retrospective Analysis on Behalf of the Polish Adult Leukemia Group
by: Ugo Giordano, et al.
Published: (2025-01-01)

Pengaruh Likopen terhadap Kadar Soluble FMS-Like Tyrosine Kinase 1 pada Preeklamsi
by: Vaulinne Basyir, et al.
Published: (2021-02-01)

The Expression and Clinical Significance of Different Forms of Mer Receptor Tyrosine Kinase in Systemic Lupus Erythematosus
by: Huaqun Zhu, et al.
Published: (2014-01-01)

Retraction: Bruton’s tyrosine kinase inhibition attenuates the cardiac dysfunction caused by cecal ligation and puncture in mice
by: Frontiers Editorial Office
Published: (2025-01-01)

A review on the potential of Bruton’s tyrosine kinase (Btk) inhibitor – Ibrutinib for treatment of Multiple Myeloma (MM)
by: Sze-Ting Bong, et al.
Published: (2019-05-01)

Utility of Bruton’s Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström’s Macroglobulinemia)
by: Maroun Bou Zerdan, et al.
Published: (2022-01-01)

The tyrosine kinase inhibitor lenvatinib is oxidized by rat cytochromes P450 and affects their expression in rat liver
by: Indra Radek, et al.
Published: (2024-09-01)

Rechallenge therapy versus tyrosine kinase inhibitor (TKI) for advanced metastatic colorectal cancer: a retrospective study
by: Chenming Liu, et al.
Published: (2025-02-01)

Functional interaction between receptor tyrosine kinase MET and ETS transcription factors promotes prostate cancer progression
by: Elisa Carouge, et al.
Published: (2025-02-01)

Patients outcomes in lung adenocarcinoma transforming to small-cell lung cancer after tyrosine kinase inhibitor therapy
by: Shuai Wang, et al.
Published: (2025-02-01)

Comparative safety profile of tyrosine kinase inhibitors in NSCLC: a network meta-analysis of hypertension and thrombotic risks
by: Mingming Tan, et al.
Published: (2025-01-01)

Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
by: Soomin Kim, et al.
Published: (2025-02-01)

Cell-free expression and SMA copolymer encapsulation of a functional receptor tyrosine kinase disease variant, FGFR3-TACC3
by: Alexander J. D. Snow, et al.
Published: (2025-01-01)

Characterization of Interleukin-15-Transpresenting Dendritic Cells for Clinical Use
by: J. M. J. Van den Bergh, et al.
Published: (2017-01-01)

Phosphate-modified CpG oligonucleotides induce in vitro maturation of human myeloid dendritic cells
by: A. A. Ostanin, et al.
Published: (2020-10-01)

Plasmacytoid Urothelial Carcinoma of the Bladder Metastatic to the Stomach: A Case Report
by: Philippe Nabbout, et al.
Published: (2012-01-01)

Using In Silico Methods to Identify Protein Tyrosine Kinase A (PtkA) Homolog in Non-Tuberculous Mycobacteria (NTM)
by: Swati Jaiswal, et al.
Published: (2024-11-01)

Therapeutic effect of selective interleukin-2-inducible tyrosine kinase inhibitor in orbital fibroblasts from patients with Graves’ orbitopathy
by: Yeonjung Yoon, et al.
Published: (2024-09-01)

Contralateral Renal Cell Carcinoma Ureteric Metastases Can Arise on Tyrosine Kinase Adjuvant Therapy and Be Effectively Treated by Endoscopic Laser Excision and Ablation
by: Sarah L. Reid, et al.
Published: (2014-01-01)